Injectable aqueous implant formulation containing ascorbic acid
US10918592B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2020 |
| Grant date | Feb 16, 2021 |
| Priority date | — |
| Expiry date | Jun 12, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2430/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An injectable aqueous implant formulation, and processes for making and using the formulation, wherein the injectable aqueous implant formulation has been sterilized by gamma-ray or X-ray-irradiation and can be extruded through a tapering system and an 18 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N, which comprises 25-45 w/w % of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm as determined by sieving and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 1.8 to 4.5, which contains at least 0.05% (w/w) ascorbic acid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.